BioTrove and Blue Sky Introduce Screening Solution Portfolio
News Mar 22, 2006
BioTrove, Inc. and Blue Sky Biotech, Inc. have announced a collaborative effort to provide a service solution, utilizing mass spectrometry-based high-throughput screening assays on previously unscreenable drug targets.
Blue Sky will provide pharma-grade proteins that pharmaceutical companies can quickly screen against their entire small molecule libraries.
BioTrove will utilize its proprietary RapidFire™ screening technology that has screened millions of compounds.
The collaboration will initially focus on high value targets in key therapeutic areas such as metabolic disorders and oncology.
Specific examples of current projects include acyl-coenzyme A diacylglycerol acyltransferase (DGAT), 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD), desaturases, and a family of histone deacetylases (HDACs).
BioTrove's RapidFire™ screening technology combines micro-fluidics and high-throughput mass spectrometry to identify lead compounds against a wide variety of challenging enzymatic targets.
High throughput assays are rapidly developed and utilize the direct detection of native, label-free substrate and product. This allows screening of a wide variety of targets, including many that are difficult or impossible to screen with conventional approaches.
"We are excited to offer the pharmaceutical community a complete HTS solution around a suite of enzymatic targets that clearly have high thereapeutic and economic value. This relationship will expand our growing list of pharmaceutical business partners," said Can ‘Jon’ Ozbal, director of RapidFire technologies at BioTrove.
"The unique combination of RapidFire™ HTS technology and Blue Sky Biotech's reagent provision expertise will provide our mutual customers with an immense competitive advantage in drug-discovery," said Paul Wengender, president of Blue Sky Biotech.
Worldwide Clinical Trials Receives 2018 CRO Leadership AwardsNews
Life Science Leader and Industry Standard Research assess 70 contract research organizations, honoring Worldwide Clinical Trials for fifth consecutive year.READ MORE
WuXi Biologics to Invest in Biologics Manufacturing Facility in SingaporeNews
WuXi Biologics' first overseas site in Asia.READ MORE
Missing Link Between Blow Flies and Possible Pathogen TransmissionNews
Determining whether blow flies have consumed animal fecal material versus animal tissue has important implications for both human public health and animal conservation. A recent study shows how that determination can be made.READ MORE